# Preclinical Translational Cancer Research Program

> **NIH NIH P30** · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2021 · $53,817

## Abstract

PRECLINICAL TRANSLATIONAL CANCER RESEARCH PROGRAM – ABSTRACT
The goal of the Preclinical Translational Cancer Research (PTCR) program at the Stephenson Cancer Center
(SCC) is to promote and accelerate scientific discovery and development of ideas in order to improve the
prevention, diagnosis and treatment of cancer. PTCR members represent broad transdisciplinary expertise,
from elucidating basic mechanisms of tumorigenesis to conducting preclinical translational research, creating a
robust environment for the generation and translation of ideas. The program Specific Aims are: 1) to discover
cellular mechanisms that regulate tumor growth, progression and response to therapy; 2) to determine the
functional mechanisms underlying tumor cell-stroma interactions leading to tumor progression and metastasis;
and 3) to develop novel tools and applications for nanomaterial and imaging technologies that enhance cancer
detection, response prediction and treatment.
Highlights of the PTCR program include: 1) highly interactive teams of basic discovery and translational
scientists organized to advance specific aims; 2) a strong team of basic discovery researchers with a track
record of high-impact publications and peer-reviewed funding at the Oklahoma Medical Research Foundation
(OMRF), the SCC's proposed consortium partner; 3) integrated and collaborative research with nanomaterials
and imaging investigators at OU Norman; 4) access to SCC shared resources, which provide state-of-the-art
technologies and services to support program science; 5) disease-site focused transdisciplinary research
teams in colorectal and pancreatic cancers, supported by SCC developmental funds, that are developing multi-
PI grant applications; and 6) a strong focus on mentoring highlighted by an NIH-funded Center of Biomedical
Research Excellence P20 grant.
The PTCR program has 46 members that represent 19 departments and two institutions (OU and OMRF),
illustrating its transdisciplinary expertise. It is also highly collaborative: of the 15 PTCR pilot projects funded
over the past two years, 10 have intra- and seven have inter-programmatic collaborations. As of December 31,
2016, program members were awarded $6,525,844 in annual NCI and other peer-reviewed cancer-related
support (direct cost). NCI funding ($2,915,115) accounts for 44.7% of the peer-reviewed funding, highlighting
the program's cancer focus. Total annual PTCR program funding is $9,101,794 (direct cost). For the five-year
reporting period (2012-2016), PTCR program members published 446 peer-reviewed articles, of which 16.4%
included intra-programmatic, 6.1% included inter-programmatic, and 69.7% included inter-institutional
collaborators. For 2016, inter-programmatic publications increased to 14.9%, highlighting the growing number
of collaborations underway with the Gynecologic Cancers (GC) and Cancer Prevention and Control (CPC)
programs.

## Key facts

- **NIH application ID:** 10177892
- **Project number:** 5P30CA225520-04
- **Recipient organization:** UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
- **Principal Investigator:** MIN LI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $53,817
- **Award type:** 5
- **Project period:** 2018-05-01 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10177892

## Citation

> US National Institutes of Health, RePORTER application 10177892, Preclinical Translational Cancer Research Program (5P30CA225520-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10177892. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*